Natural product inspired library synthesis -Identification of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran based inhibitors of Chlamydia trachomatis. 
Introduction
Natural products have been a valuable source to identify candidates for drug discovery and development [1e3] . Our interest in biologically active natural products originates from the identification of the plant derived resveratrol tetramer, (À)-hopeaphenol ( Fig. 1) , as an antibacterial agent that blocks the type III secretion system in Pseudomonas aeruginosa and Yersinia pseudotuberculosis without affecting bacterial growth [4, 5] . In addition, we found that (À)-hopeaphenol reduced cell entry of the obligate intracellular sexually transmitted pathogen Chlamydia trachomatis [4] . (À)-Hopeaphenol, the first characterized resveratrol oligomer, is based on a 2,3-trans-diaryl-2,3-dihydrobenzo[b]furan scaffold. Benzofuran and 2,3-disubstituted benzofuran moieties are widespread in nature and present in a large number of natural products that display numerous biological activities, including antibacterial, antifungal, antiviral, antioxidant, anti-inflammatory and anticancer activities ( Fig. 1) [6e10]. For example, 2-substiuted-3H-benzofurans and 3-benzoyl-2-aryl benzofurans were reported as antibacterial against Mycobacterium tuberculosis H37Rv and methicillinresistant S. aureus (MRSA) respectively [8] .
In the present study, we designed, synthesized, and characterized a natural-product-like screening library based on 2,3-diarylbenzo [b] furan and 2,3-diaryl-2,3-dihydrobenzo[b]furan scaffolds to explore these scaffolds as a source for novel antibacterial compounds. This compound collection was interrogated in a number of phenotypic and biochemical screening assays leading to identification of potent inhibitors that block intracellular replication of the Gram-negative pathogen C. trachomatis. To the best of our knowledge there no benzofurans besides (À)-hopeaphenol that have previously been reported to display antibacterial activity against C. trachomatis.
C. trachomatis is a clinically important pathogen that causes over 100 million cases of sexually transmitted disease annually [11e13] , which may give rise to infertility [14] . Furthermore, trachoma, an ocular infection caused by C. trachomatis, is responsible for preventable blindness [15] . More specific treatment of Chlamydia infections would be beneficial compared to the broad-spectrum antibiotics used today, which have a long-lasting effect on our commensal microbiota and contribute to the development of antibiotic resistance. These new anti-chlamydial compounds constitute starting points for the development of specific treatments that reduces the global burden of C. trachomatis infections.
Results and discussion

Synthesis
An overview of benzofurans synthesis
While 2,3-disubstituted benzofurans can be readily prepared [16e22], only few reports describe efficient methods for the synthesis of 2,3-diaryl-2,3-dihydrobenzofurans and they mostly focus on the total synthesis of their parental natural products [23e26] . Wai-Hung et al. applied ruthenium porphyrins and in situ generated diazo compounds to synthesize cis-2,3-disubstituted-2,3-dihydro-benzofurans via carbenoid C-H insertion [23] . However, only one example of a non-substituted 2,3-diaryl-2,3-dihydrobenzofuran was disclosed. In a recent report Soldi et al. [24] elegantly carried out enantioselective synthesis of resveratrolbased natural products containing the 2,3-dihydrobenzofuran scaffold by applying carbenoid C-H insertion with chiral dirhodium catalyst [24, 27] . This approach was also applied for the total synthesis of (À)-E-d-viniferin [26] .
We have previously completed the total syntheses of (±)-ampelopsin B and (±)-ε-viniferin [28] (Fig. 1) , and more recently we reported the total syntheses of other polyphenolic nature products including viniferifuran, a resveratrol-picetannol hybrid and anigopreissin A [29] . To extend the scope of our studies on benzofuran-based natural products, we recently designed and synthesized a library based on 3-carboxy 2-aryl benzofuran and 3-carboxy 2-aryl trans 2,3-dihydrobenzofuran scaffolds [30] .
Synthesis of 2,3-diarylbenzo[b]furans series
In this study, we thought to synthesize a set of 2,3-diarylbenzo [b]furans as precursors to access cis-and trans-2,3-diaryl-2,3-dihydrobenzofuran via catalytic hydrogenation followed by epimerization based on our earlier results (Scheme 1) [31] . The synthesis of 2,3-diarylbenzo[b]furan was achieved by utilizing efficient one-pot multicomponent reactions reported by Cacchi [32] , Flynn [16, 33] , and Larock [18] . It starts with Sonogashira coupling A) B) Fig. 1 . A) Structures of natural oligomeric resveratrol based on benzofuran and 2,3-diaryl-benzofuran scaffolds including (À)-hopeaphenol [67, 68] . B) An overlay of energyminimized conformers of cis-2,3-diaryl-2,3-dihydrobenzofuran, trans-2,3-diaryl-2,3-dihydrobenzofuran and 2,3-diarylbenzofuran (created in Schr€ odinger Maestro version 10.5.014).
between an aryl alkyne and 2-iodophenol. Subsequently, one-pot heteroannulative coupling with aryl iodides affords the 2,3-diarylbenzo[b]furan as depicted in Scheme 2. The library was then designed by selecting nine commercially available aryl iodides (A1eA9), three 2-iodophenols (B1eB3), and two aryl-alkynes (C1 and C2) to probe the chemistry outlined in Scheme 1 (Fig. 2) . The two selected aryl-alkynes, 1-ethynyl-4-methoxybenzene (C1) and 1-ethynyl-4-benzyloxybenzene (C2), carry para protected hydroxyl group that is mechanistically required to assist the final epimerization under acidic condition as depicted in Scheme 1 [28, 31] . Synthesizing all combinations would have yielded fifty-four molecules. To evaluate the feasibility of the chemistry, a representative subset of twenty-eight molecules was selected.
The microwave-assisted one-pot three-component reaction (Scheme 2) reported by Markina et al. [18] allowed the synthesis of compounds 1e8 (Table 1) with the non-substituted 2-iodophenol B1 in 35e91% yields. Unfortunately, this reaction resulted in low yield or no product when using 2-iodo-5-methoxyphenol B2, or 4-fluoro-2-iodophenol B3. This is due to that the initial Sonogashira coupling with both 4-methoxy phenyl acetylene C2 and 4-benzyloxy phenyl acetylene C3 resulted in premature cyclization to give 2-substituted benzo[b]furans (P-II, compound 9) as product instead of the intermediate 2-(1-alkynyl) phenol (P-I) leading to the required target 2,3-diarylbenzofuran (P-III) (Scheme 3a) [16, 18] . We, therefore, turned to a method reported by Chaplin and Flynn [16] (Scheme 2) in which two equivalents of Grignard reagent (CH 3 MgCl) was used to mask the phenol and to eliminate the possibility of the premature cyclization. This method allowed the synthesis of the remaining benzofuran series, compounds 10e16 in 45e91% yields (Table 1) . To expand our library further, variation of functional groups was achieved by demethyaltion of the phenolic groups with BBr 3 (Scheme 4) to yield the corresponding phenolic compounds 17e25 in 62e99% yields (Table 1) .
Synthesis of cis-and trans-2,3-diaryl-2,3-dihydrobenzofurans series
We then used our knowledge from the total synthesis of (±)-ampelopsin B and (±)-ε-viniferin [28] to synthesize the corresponding cis-dihydrobenzofurans via catalytic hydrogenation. We were able to achieve 30e60% conversion of several benzofurans into the corresponding cis-dihydrobenzofurans using highpressure hydrogenation (5 bar) and Pd(OH) 2 as a catalyst in iPrOH. However, it was not possible to obtain full conversion of the starting material while avoiding benzyl ether cleavage as a consecutive reaction (Scheme 3b). Various heterogeneous and homogenous catalysts as well as reaction conditions and solvents were screened (data not shown). Nevertheless, we could not identify a reliable and efficient hydrogenation method that can be employed for a divergent synthesis to complete the library. These results are congruent with our findings during the attempts to synthesize 3-carboxy 2-aryl cis-2,3-dihydrobenzofurans [30] . Thus, due to these limitations the strategy to obtain dihydrobenzofurans outlined in Scheme 1 was abandoned.
We instead rerouted the synthetic strategy to synthesize dihydrobenzofurans via intramolecular carbenoid C-H insertion using salicylaldehydes, aryl iodides and benzyl halides as depicted in Scheme 5. We selected aryl iodides A5eA11, three salicylaldehydes D1eD3 corresponding to iodophenols B1eB3, and two different benzyl bromides E1 and E2 as shown in Fig. 2 . From all possible forty-two combinations a representative subset of fourteen compounds in the form of cis and trans isomers was selected.
We exploited the ruthenium porphyrin catalyst [23] to synthesize cis-trans diastereomeric mixtures that can be readily separated (Scheme 5). The 2-hydroxydiarylketones (P-IV) are key intermediates in this pathway and they are typically prepared by addition of organolithium or Grignard reagent to aryl aldehyde followed by oxidation [24, 26] . However, while this procedure is straightforward, it often requires protection and deprotection of various base sensitive functionalities. In this work, we instead applied direct catalytic arylation of aldehydic C-H using palladium chloride to obtain P-IV as pluripotent intermediates [34] . The salicylaldehydes were coupled to the aryl iodides using palladium chloride to afford the corresponding 2-hydroxylarylketones in 40e93% yields (Scheme 5). Subsequently these were O-alkylated with two different benzyl bromides to afford intermediates P-V in essentially quantitative yields (Scheme 5). Aryl tosylhydrazones (P-VI) were prepared from the corresponding ketone in 70e99% yields by condensation with p-toluenesulfonylhydrazide, which was then used as precursors for the carbenoid C-H insertion. Eventually, twostep one-pot ruthenium carbenoid intramolecular C-H insertion afforded a racemic cis-trans mixture of the dihydrobenzofurans (P-VII) via in situ generation of diazo compounds. In this study, we used commercially available ruthenium porphyrin (RuII(TPP)CO), which yielded a racemic cis-trans mixture in a ratio of 1:1e1:3 and 27e70% yields over two steps (Table 2 ). This diastereomeric mixture was subsequently resolved by HPLC and the stereochemistry was verified through the J coupling constants (see supporting information Fig. S6 ). For compounds 28, 37, 44 and 48 only the trans isomer was isolated in >95% purity, while the cis isomer was only >85% pure in a mix with the trans isomer.
We have thus explored the chemistry of 2,3-diarylbenzofurans and demonstrated a facile construction of both 2,3-diarylbenzofurans as well as cis-and trans-2,3-diaryl-2,3-dihydrobenzofurans libraries. These methods can be further expanded to construct different libraries of natural products-like compounds based on benzofuran and 1H-indole scaffolds.
Biological evaluation 2.2.1. Biological screening
The 2,3-diarylbenzofurans and 2,3-diaryl-2,3-dihydrobenzofurans (Tables 1 and 2) were then evaluated in a number of biological assays. Biochemical screening was performed to identify inhibitors of the ADP-ribose transferase activity of the P. aeruginosa toxin ExoS [35] , the Y. pseudotuberculosis phosphatase YopH [36] , and the acetaldehydedehydrogenase activity of AdhE from Escherichia coli [37, 38] . Phenotypic screening was executed with a Y. pseudotuberculosis luciferase reporter-gene assay for identification of type III secretion system inhibitors [39] , a lipase reporter assay for the twin arginine translocation (tat) system in P. aeruginosa [40, 41] , and image-based screening for compounds that block intracellular replication of C. trachomatis in HeLa cells [42] . Active compounds were only identified in the C. trachomatis screen indicating that the compound library does not contain frequent hitters.
Identification of anti-chlamydial compounds
The 
Cytotoxicity profile of the identified anti-chlamydial
A toxic effect on the HeLa cells results in a reduction of Chlamydia inclusions and thus obscures deduction of structure-activity relationships. The resulting twenty-six primary hits were then subjected to extended cytotoxicity testing using the XTT reduction assay [43] . This led to the exclusion of additional six compounds due to their dose-dependent toxicity (see supporting information Table S1 ). The remaining non-toxic twenty compounds were subjected to full dose-response analysis at eleven concentrations and subsequent determination of IC 50 values (i.e. 50% inhibition of control Chlamydia inclusion) ( Table 3 , supporting information Fig. S5 ). From the 2,3-diarylbenzofuran series 11 compounds showed anti-chlamydial activity with a reproducible IC 50 values between 2 and 27 mM (Table 3 ) and hill-slope [44, 45] values of 1e2.
Representative immunofluorescence images for dose-response analysis of compounds 1, 3 and 44 are shown in Fig. 3 .
Structure-activity relationships
In terms of structure-activity relationships, compounds 1, 3, 12, and 16, the top potent inhibitors with IC 50 below 5 mM all contain a pyridyl moiety as a substituent on position 3 of the benzofuran. Moreover, compounds 3, 12 and 16, the most potent analogues with IC 50 of 2.0, 2.7 and 4.2 mM respectively, all shared the 2-flouro-4-pyridyl and the 4-methoxyphenyl substituents on position 3 and 2 of the benzofuran respectively, while their potency appear to be less affected by substitution on the fused ring. This trend in activity is valid also for the less potent analogues 7, 11, and 15, that carry a 4-methoxyphenyl substituent on position 3. The 2,3-diarylbenzofurans with free phenolic groups were generally cytotoxic in the primary screening (see supporting information Fig. S2  B) and even the few compounds that passed the primary screening cut-offs (i.e. 17, 18, 19, 23, and 25) were later eliminated in 
Scheme 3. Synthetic challenges faced during the syntheses of 2,3-diarylbenzofuran and 2,3-dihydrobenzofuran. a) Synthesis of 2,3-diarylbenzofurans via 2-(1-alkynyl) phenol P-I showing the premature cyclized product P-II. b) Hydrogenation reaction showing the inevitable benzyl ether cleavage and ring opening.
the extended toxicity evaluation using the XTT assay (see supporting information Table S1 ). This data indicate the need for protected phenols in order to reduce the toxicity. When comparing compounds 1 and 3 with their benzyl-protected analogues, 6 and 4 respectively, it is clear that the large benzyl group reduces potency possibly due to steric factors and/or increased lipophilicity. In the 2,3-diaryl-2,3-dihydrobenzofurans series the eight nontoxic hit compounds displayed weak C. trachomatis inhibition with IC 50 typically above 20 mM (Table 3 ). In contrast to the 2,3-diarylbenzofuran series, all compounds that belong to the 2,3-diaryl-2,3-dihydrobenzofuran series featured steep dose-response curves and hill-slope values typically exceeding 3.5 [44, 45] (see supporting information Fig. S5 ). This group of inhibitors is thus less attractive for further investigations. One intriguing exception is the non-toxic compound 44, which showed a reproducible activity with IC 50 of 0.9 mM. It cannot be excluded that this compound has a different mode of action than the potent 2,3-diarylbenzofurans i.e. 1, 3, 12 and 16.
Comparable activity with clinically-used antibiotics
We then proceeded to benchmark the most potent compounds (1, 3, 12, 16 and 44) by comparing them to ofloxacin and azithromycin, two antibiotics used in the clinic to treat C. trachomatis infections [46] . Ofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase [47] , while azithromycin is a macrolide antibiotic that inhibits bacterial proteins synthesis by binding the ribosome 50 S subunit [48] . The compounds demonstrated comparable IC 50 values to the antibiotics (Table 4 ) and the slope of the IC 50 curves was less steep for the compounds compared to the antibiotics (Fig. 4) . The most potent compound, 44, was however as potent as antibiotics, and thus constitute a promising starting point for further development.
Efficacy against chlamydia strains serovar A and serovar D
As a final step, compound 1, 3, 12, 16 and 44 were evaluated against two other different Chlamydia strains, serovar D and serovar A. Serovar D is one of the most prevalent C. trachomatis genital tract isolate worldwide [49, 50] , while serovar L2, which was used for the primary evaluation, is less common and more virulent causing the locally disseminated lymphogranuloma venerum infections. Both serovars are associated with variety of genital infections, but also neonatal infections [14, 50, 51] . In contrast, serovar A associates with ocular trachoma, which is a leading cause of infectious blindness worldwide [14, 15, 51] . We found that the compounds are equally active against all strains with IC 50 values in the range of 0.079e5 mM (Table 4 and Fig. 4 ).
Distinct mode of action compared to (À)-hopeaphenol
Giving that this novel anti-chlamydial class are based on the scaffold of the natural product (À)-hopeaphenol, we compared their inhibition profile with that of (À)-hopeaphenol. (À)-Hopeaphenol displays anti-chlamydial activity but only if the bacteria are pretreated with 13e100 mM of the compound 1 h before the infection of eukaryotic cells [4] . The lack of effect when adding bacteria and compound simultaneously to the host cells is most likely due to poor membrane permeability of (À)-hopeaphenol. Furthermore, it was established that (À)-hopeaphenol irreversibly inhibits the T3S in Y. pseudotuberculosis [4] . In contrast, the 2,3-diarylbenzofuran class does not block the T3S in Y. pseudotuberculosis and efficiently inhibits the intracellular replication of Chlamydia without the need for pretreatment. Altogether, this data suggest that the mechanism behind the antichlamydial activity of the benzofurans is distinct from the mode of action of (À)-hopeaphenol.
In-silico assessment of pharmacological properties
At this point of early drug discovery process, it was then important to incorporate an assessment of the pharmacological properties for those anti-chlamydial candidates. Membrane permeability is one of the most important factors in drug absorption, but also it is a crucial factor when it comes to the development of antibacterial [52] . Bypassing bacterial membranes has always been a challenging aspect particularly in Gram-negative organisms where the drug needs to penetrate outer membrane, inner membrane, and peptidoglycan layer [52] . In case of C. trachomatis additional permeability barriers are formed since Chlamydia is an obligate intracellular pathogen and a drug act intracellularly has to cross the host cell plasma membrane and inclusion membrane. We therefore applied in silico calculation of physicochemical properties including cell permeability and lipophilicity for the top potent inhibitors 1, 3, 12, 16, and 44 using QikProp program (Schr€ odinger, a All cis and trans compounds are racemic. b Isolated yield over two-step, one-pot reaction and after column chromatography and HPLC separation of the diastereomeric mixture. All reactions have been performed once and no attempts were made to improve the yields. c A single isomer was isolated as the other isomer was not stable, thus the relative stereochemistry could not be assigned unambiguously. LLC, New York, NY, 2017) (see supporting information Table S2 ). We used two different in silico models, Caco-2 [53] and MDCK [54] , to predict permeability through the intestinal epithelial barriers. It appears that all compounds showed enhanced calculated Caco-2 and MDCK membrane permeability as well as drug likeness properties (supporting information Table S2 ). Clearly, the most potent inhibitor 44 appeared to have the highest permeability rate with >9900 nm/s. Taken together this result support our hypothesis regarding the need for these antibacterial compounds to cross the host cell membrane and maybe the bacterial inclusion membrane if this class of inhibitors target proteins or other components residing inside the inclusion body of C. trachomatis.
Conclusions
In conclusion, we have synthesized natural product-inspired compound libraries based on 2,3-diarylbenzofuran and 2,3-diaryl-2,3-dihydrobenzofuran. A phenotypic screening of this library against Chlamydia infection allowed us to identify non-toxic and potent small-molecules that inhibit strains representing all clinical presentations of C. trachomatis, serovar L2, D and A infection with IC 50 values in the range of 0.079e3 mM and thus similar to ofloxacin and azithromycin. These small molecules are structurally distinct, yet more potent or in the same range of potency as known antichlamydial compounds e.g. salicylacylhydrazides [55e58], 8-hydroxyquinoline based inhibitors [59] , N-acylated derivatives of sulfamethoxazole and sulfafurazole [42] , salicylacylhydrazide sulfonamide hybrids [60] , the Chlamydia protease inhibitor-peptide Boc-Val-Pro-ValP(OPh2) (JO146) [61, 62] , the isoflavone biochanin A [63] , dibenzocyclooctadiene lignans [64] , thiadiazinons [65] and 2-pyridones [66] . These novel anti-chlamydial compounds can thus serve as starting points for a continued medicinal chemistry programs, lead optimization, and the development of a novel antichlamydial drug. Importantly, Chlamydia inhibitors, such as 
Experimental section
General chemistry
All reactions were carried out under inert atmosphere (N 2 gas). Chemicals and reagents were purchased from Aldrich, Alfa Aesar, AK Scientific, Matrix Scientific or Apollo Scientific. 5,10,15,20-tetraphenyl-21H,23H-porphine ruthenium(II) carbonyl (RuII(TPP) CO) was purchased from Aldrich. Organic solvents were dried using the dry solvent system (Glass Contour Solvent Systems, SG Water USA) except CH 3 CN, CH 3 OH, PhCH 3 and DMSO, which were dried over activated molecular sieves 3 Å. Microwave reactions were performed in Biotage Initiator. Flash chromatography was performed on Biotage Isolera One using appropriate SNAP Cartridge KP-Sil or SNAP Ultra HP-Sphere 25 mm, and UV absorbance at 254 nm. TLC was performed on Silica gel 60 F 254 (Merck) with detection by UV light unless staining solution is mentioned. Preparative HPLC separation were performed on Gilson System HPLC, 3-(2-(4-methoxyphenyl)benzofuran-3-yl)pyridine, 1: 2-Iodophenol (1.14 mmol, 250 mg) and Pd(Ph 3 P) 2 Cl (5 mol%, 40 mg) were placed in a 20 mL microwave vial, and purged with N 2 . Dry THF (0.8 mL) was added and the mixture was stirred until the iodophenol was completely dissolved. Then dry triethylamine (2 mL) and a solution of CuI (3 mol%, 5.4 mg) in triethylamine (1 mL) were added and the mixture was stirred for 10 min. 4-Ethynylanisole (1.2 equiv., 180.3 mg) in THF (0.5 mL) was then added under N 2 , and the mixture was stirred in the microwave reactor for 30 min at 40 C. The corresponding 3-iodopyridine (1.2 equiv., 279.6 mg) in dry CH 3 CN (3.7 mL) was added under N 2 , and the reaction mixture was heated in the microwave reactor at 100 C for 30 min. The reaction was monitored with TLC and LC-MS. After cooling, the solvents were evaporated and the product was purified on silica followed by preparative HPLC (25 / 100% B over 25 min).
Method B (Examplified by compound 12) (Scheme 2 B): [16] 2-fluoro-4-(6-methoxy-2-(4-methoxyphenyl)benzofuran-3-yl) pyridine, 12: To a solution of the 2-Iodo-5-methoxyphenol (1 mmol, 252 mg) and the 4-Ethynylanisole (1.2 equiv., 166 mg) in dry THF (1.6 mL, 0.6 M of the Iodophenol), at 0 C under N 2 , was added CH 3 MgBr (THF solution, 2.3 M, 2 equiv., 0.792 mL) dropwise. The mixture was allowed to warm to room temperature, and Pd(Ph 3 P) 2 Cl (3 mol%, 21.3 mg) was added before the mixture was heated to 65 C for 2 h under N 2 . The reaction mixture was then cooled to room temperature and the THF was removed under reduced pressure. DMSO (2 mL) was added to the residue followed by addition of 2-Fluoro-4-iodopyridine (1.2 equiv., 269.7 mg) and the mixture was heated to 80 C for 4 h under N 2 . The mixture was cooled to room temperature and diluted with EtOAc, washed with H 2 O and brine. The organic phase was dried over Na 2 SO 4 , concentrated and purified on silica followed by preparative HPLC (25 / 100% B over 25 min).
General procedure for the deprotection of the permethylated compounds
Method C (Scheme 4): To a solution of permethylated compound (0.53 mmol, 170 mg) in dry DCM (5 mL, 0.1 M) at À78 C was added dropwise BBr 3 (0.136 mL, 1.5 equiv./OCH 3 ). The mixture was stirred and allowed to reach room temperature overnight. The reaction was monitored with TLC (DCM/CH 3 OH 10%)/Heptane 7:3 and LC-MS, and quenched by addition of ice-cold saturated aqueous solution of NaHCO 3 dropwise. The mixture was diluted with EtOAc and washed with H 2 O and brine. The organic phase was dried over Na 2 SO 4 , concentrated under vacuum and purified on silica using (DCM/CH 3 OH 10%)/Heptane 7:3 to afford the corresponding phenol in quantitative yield. The compounds were also purified on preparative HPLC (25 / 100% B over 25 min). . The reaction mixture was filtered over a pad of Celite, diluted with EtOAc, washed 3 times with water, and the aqueous layers was acidified and extracted twice with EtOAc. The combined organic layers was dried over Na 2 SO 4 , concentrated and purified on silica using EtOAc/Heptane 1:20 / 1:9 step gradient) to afford 2 0 -hydroxybenzophenone in 69.3% yield. (NMR data is given in the supporting information).
General procedure for the synthesis of 2
0 -benzyloxybenzophenone.
Method E: (3,4-difluorophenyl)(4-methoxy-2-((3-methoxybenzyl)oxy) phenyl) methanone: To a solution of (3,4-difluorophenyl)(2-hydroxy-4-methoxyphenyl)methanone (0.56 mmol) in acetone (0.25 M, 2.4 mL) anhydrous K 2 CO 3 (2 equiv., 157 mg) and KI (1 equiv., 94.3 mg) were added followed by 3-Methoxybenzyl bromide (2 equiv., 0.159 mL), and the mixture was refluxed and monitored with TLC (EtOAc/Heptane 1:3) till completion. After cooling to room temperature, the mixture was filtered, concentrated and purified on silica using EtOAc/Heptane (1:20 / 1:3 step gradient) to afford 2 0 -benzyloxybenzophenone in 96.7% yield. (NMR data is given in the supporting information).
General procedure for the synthesis of tosylhydrazones.
Method F:
oxy)phenyl)methylene)-4-methylbenzenesulfonohydrazide: To a rapidly stirred solution of p-toluenesulphonohydrazide (2.08 mmol, 387.6 mg) in dry CH 3 OH (0.6 mL, 3 M) at 60 C was added dropwise a solution of 2 0 -benzyloxybenzophenone (0.52 mmol, 200 mg) in dry CH 3 OH (1 mL, 0.5 M). The reaction was stirred at reflux and monitored with TLC (EtOAc/Heptane 1:2) till completion. The product was precipitated as crystalline, which was filtered off and washed with ice-cold CH 3 OH. The remaining reaction mixture and the filtrate was concentrated and purified on silica using (EtOAc/Heptane 1:2) to afford tosylhydrazone in 78.6% yield. (NMR data is given in the supporting information) . At 1 h post infection, the inoculum was replaced with RPMI media supplemented as above and containing 0.5% DMSO and serial 1:1 dilutions of the tested compounds, starting at 50 mM and reaching 0.1953 mM. The infection was allowed to proceed for 44e48 h before fixation by aspiration of the media and adding methanol for 5 min. Chlamydial inclusions were stained with an inhouse generated primary rabbit anti-Chlamydia antibody [42] and a secondary donkey anti-rabbit FITC-labeled antibody (Jackson ImmunoResearch, West Grove, PA, USA). The DNA of the cells and Chlamydia was stained by DAPI. The number of inclusions exceeding 130 square microns in size were counted by an ArrayScan VTI HCS automated reader (Thermo Scientific, Waltham, PA, USA). Inhibition of Chlamydia was evaluated as the number of inclusions in compound treated infection compared to the numbers of inclusions in DMSO treated control infections (% of control). IC 50 values are representative of at least three independent experiments. The data analysis was performed using nonlinear regression (curve fit) in GraphPad Prism v.5. For microscopy, HeLa299 cells were inoculated onto glass coverslips in 24 well plates. Cells were infected with Chlamydia, treated with compounds, fixed and stained as described, but using a rhodamine-labelled anti-rabbit antibody (Jackson ImmunoResearch, West Grove, PA, USA). Infected cells were observed on a Nikon 90i Fluorescent Microscope using a 20x objective.
XTT reduction assay
HeLa299 cells were inoculated into 96 well plates with a density of 7000 cells per well and cultured overnight at 37 C with 5% CO 2 in RPMI 640 supplemented with 10% FBS and 2 mM L-glutamate. The following day, the RPMI was replaced with DMEM without Phenol Red (Life Technologies, Carlsbad, CA, USA) containing 0.5% DMSO with or without test compounds at 25 and 50 mM concentrations, with at least three replicate wells for each compound concentration, and incubated at 37 C with 5% CO 2 for 48 h. Wells containing no cells were used as blank controls. Following this incubation with compounds, the XTT Cell Proliferation Assay kit was used according to the manufacturer's instructions (ATCC, Manassas, VA, USA). Briefly, activation reagent and XTT reagent were thawed at 37 C, then mixed in a 1:50 ratio with enough volume to add 50 mL to each well. The plates were placed in the 37 C incubator for 2.5 h. The absorbance of each well was then read at 475 nm and 660 nm with a Tecan Infinite m200 plate reader (Tecan, M€ annedorf, Switzerland). To analyze the data, the 660 nm reading was subtracted from the 475 nm reading to help eliminate non-specific readings from the assay results. Average blank control well readings were subtracted from those containing cells. Final readings from wells containing compound were compared to DMSO-only control wells and expressed as a percent (% of control).
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